Perioperative immunotherapy, given before and after surgery, significantly improves event-free survival in patients with early-stage non-small cell lung cancer compared to chemotherapy alone. Results from the Phase III CheckMate 77T study showed a 42% reduction in the risk of disease progression, recurrence, or death with perioperative nivolumab. Patients receiving this combination also had higher rates of complete and major pathological response. The study supports perioperative nivolumab as an effective approach to reduce the risk of lung cancer relapse in operable patients. This data was presented at the 2023 European Society for Medical Oncology Congress.
Source link
Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer, Phase III study finds
